143 related articles for article (PubMed ID: 32233497)
1. Monoclonal Antibody 2C5-Modified Mixed Dendrimer Micelles for Tumor-Targeted Codelivery of Chemotherapeutics and siRNA.
Pan J; Attia SA; Subhan MA; Filipczak N; Mendes LP; Li X; Kishan Yalamarty SS; Torchilin VP
Mol Pharm; 2020 May; 17(5):1638-1647. PubMed ID: 32233497
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model.
Yalamarty SSK; Filipczak N; Pathrikar T; Cotter C; Ataide JA; Luther E; Paranjape S; Torchilin V
Drug Deliv Transl Res; 2024 Aug; 14(8):2171-2185. PubMed ID: 38507033
[TBL] [Abstract][Full Text] [Related]
3. Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers.
Yalamarty SSK; Filipczak N; Li X; Pathrikar TV; Cotter C; Torchilin VP
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890364
[TBL] [Abstract][Full Text] [Related]
4. Charge reversible hyaluronic acid-modified dendrimer-based nanoparticles for siMDR-1 and doxorubicin co-delivery.
Zhang X; Pan J; Yao M; Palmerston Mendes L; Sarisozen C; Mao S; Torchilin VP
Eur J Pharm Biopharm; 2020 Sep; 154():43-49. PubMed ID: 32645383
[TBL] [Abstract][Full Text] [Related]
5. Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery.
Biswas S; Deshpande PP; Navarro G; Dodwadkar NS; Torchilin VP
Biomaterials; 2013 Jan; 34(4):1289-301. PubMed ID: 23137395
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model.
Yalamarty SSK; Filipczak N; Pathrikar T; Cotter C; Ataide JA; Luther E; Paranjape S; Torchilin V
Res Sq; 2023 Dec; ():. PubMed ID: 38168301
[TBL] [Abstract][Full Text] [Related]
7. Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model.
Perche F; Patel NR; Torchilin VP
J Control Release; 2012 Nov; 164(1):95-102. PubMed ID: 22974689
[TBL] [Abstract][Full Text] [Related]
8. Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance.
Pan J; Mendes LP; Yao M; Filipczak N; Garai S; Thakur GA; Sarisozen C; Torchilin VP
Eur J Pharm Biopharm; 2019 Mar; 136():18-28. PubMed ID: 30633973
[TBL] [Abstract][Full Text] [Related]
9. Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents.
Elbayoumi TA; Pabba S; Roby A; Torchilin VP
J Liposome Res; 2007; 17(1):1-14. PubMed ID: 17454399
[TBL] [Abstract][Full Text] [Related]
10. PEG-PE/phosphatidylcholine mixed immunomicelles specifically deliver encapsulated taxol to tumor cells of different origin and promote their efficient killing.
Gao Z; Lukyanov AN; Chakilam AR; Torchilin VP
J Drug Target; 2003 Feb; 11(2):87-92. PubMed ID: 12881194
[TBL] [Abstract][Full Text] [Related]
11. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody.
ElBayoumi TA; Torchilin VP
Clin Cancer Res; 2009 Mar; 15(6):1973-80. PubMed ID: 19276264
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice.
Gupta B; Torchilin VP
Cancer Immunol Immunother; 2007 Aug; 56(8):1215-23. PubMed ID: 17219149
[TBL] [Abstract][Full Text] [Related]
13. Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers.
Öztürk K; Esendağlı G; Gürbüz MU; Tülü M; Çalış S
Int J Pharm; 2017 Jan; 517(1-2):157-167. PubMed ID: 27965135
[TBL] [Abstract][Full Text] [Related]
14. In Vivo Antitumor Activity of Folate-Conjugated Cholic Acid-Polyethylenimine Micelles for the Codelivery of Doxorubicin and siRNA to Colorectal Adenocarcinomas.
Amjad MW; Amin MC; Katas H; Butt AM; Kesharwani P; Iyer AK
Mol Pharm; 2015 Dec; 12(12):4247-58. PubMed ID: 26567518
[TBL] [Abstract][Full Text] [Related]
15. Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies.
Elbayoumi TA; Torchilin VP
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1196-205. PubMed ID: 16763815
[TBL] [Abstract][Full Text] [Related]
16. Folic acid-decorated polyamidoamine dendrimer exhibits high tumor uptake and sustained highly localized retention in solid tumors: Its utility for local siRNA delivery.
Xu L; Yeudall WA; Yang H
Acta Biomater; 2017 Jul; 57():251-261. PubMed ID: 28438704
[TBL] [Abstract][Full Text] [Related]
17. A positron emission tomography image-guidable unimolecular micelle nanoplatform for cancer theranostic applications.
Yang J; Lu W; Xiao J; Zong Q; Xu H; Yin Y; Hong H; Xu W
Acta Biomater; 2018 Oct; 79():306-316. PubMed ID: 30172067
[TBL] [Abstract][Full Text] [Related]
18. Multifunctional polyamidoamine-modified selenium nanoparticles dual-delivering siRNA and cisplatin to A549/DDP cells for reversal multidrug resistance.
Zheng W; Cao C; Liu Y; Yu Q; Zheng C; Sun D; Ren X; Liu J
Acta Biomater; 2015 Jan; 11():368-80. PubMed ID: 25204523
[TBL] [Abstract][Full Text] [Related]
19. Nanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: In vitro evaluation on 2D and 3D tumor models.
Sarisozen C; Dhokai S; Tsikudo EG; Luther E; Rachman IM; Torchilin VP
Eur J Pharm Biopharm; 2016 Nov; 108():54-67. PubMed ID: 27569031
[TBL] [Abstract][Full Text] [Related]
20. Modulated cellular delivery of anti-VEGF siRNA (bevasiranib) by incorporating supramolecular assemblies of hydrophobically modified polyamidoamine dendrimer in stealth liposomes.
Golkar N; Samani SM; Tamaddon AM
Int J Pharm; 2016 Aug; 510(1):30-41. PubMed ID: 27291973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
